Head-to-head comparisons of medication uses, side effects, warnings, and more.
Kisqali (ribociclib) is a medication used to treat certain types of breast cancer, specifically hormone receptor–positive, human epidermal growth factor 2-negative (HR+, HER2-) breast cancer. It belongs to a drug class called CDK4/6 inhibitors, which help slow or stop cancer cells from growing. You typically take a tablet by mouth once a day for 21 days, then take 7 days off, repeating this 28-day cycle. It’s often taken together with other hormone treatments, like aromatase inhibitors or fulvestrant. Common side effects include feeling tired, nausea, and low white blood cell counts, which can make it easier to get infections.
Verzenio (abemaciclib) is a cyclin-dependent kinase (CDK) inhibitor. It’s a targeted therapy used to treat HR+/HER2- breast cancer, including early and advanced or metastatic breast cancer. Verzenio (abemaciclib) is sometimes taken alone and sometimes along with hormone therapy, depending on the stage of cancer. It comes as a pill that’s taken by mouth twice a day. Some of the more common side effects of Verzenio (abemaciclib) include nausea, diarrhea, and fatigue. Verzenio (abemaciclib) is only available as a brand-name medication.
Early breast cancer
Advanced or metastatic breast cancer
Note: Side effects listed above were reported in studies where people took Kisqali (ribociclib) with another hormone medication.
*Note: Side effect information taken from a study of Verzenio (abemaciclib) by itself for metastatic breast cancer. *
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.